Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | BCR | P11274 | 5/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282233 | 0.88 | MYC (0.58) | MYCALDH1A1HPGDPRMT5WDR77 | |
| SCHEMBL3455665 | 0.87 | HPGD (0.66) | ALDH1A1HPGDSMN1; SMN2NAMPTABL1 | |
| SCHEMBL29374171 | 0.83 | PRMT5 (0.57) | MYCALDH1A1HPGDPRMT5WDR77 | |
| SCHEMBL4518664 | 0.79 | HSD11B1 (0.49) | ALDH1A1NAMPTABL1BCRHSD11B1 | |
| SCHEMBL3281279 | 0.78 | MYC (0.58) | MYCALDH1A1HPGDSMN1; SMN2TP53 | |
| SCHEMBL3281507 | 0.78 | HDAC6 (0.69) | MYCALDH1A1HPGDSMN1; SMN2NAMPT | |
| SCHEMBL28242857 | 0.77 | PRMT5 (0.52) | MYCALDH1A1HPGDPRMT5WDR77 | |
| SCHEMBL3282215 | 0.76 | PRMT5 (0.63) | ALDH1A1HPGDPRMT5WDR77TP53 | |
| SCHEMBL3284599 | 0.76 | KMT2A (0.51) | MYCALDH1A1HPGDPRMT5WDR77 | |
| SCHEMBL1026202 | 0.76 | NOTUM (0.61) | MYCALDH1A1SMN1; SMN2PRMT5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | MYC 4493/4885ALDH1A1 681/4885HPGD 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.